A review of candidate urinary biomarkers for autism spectrum disorder

References

• Adrien JL, Barthélémy C, Lelord G, Muh JP. (1989). Use of bioclinical markers for the assessment and treatment of children with pervasive developmental disorders. Neuropsychobiology 22:117–124.
   Google Scholar
• Akil H, Owens C, Gutstein H, Taylor L, Curran E, Watson S. (1998). Endogenous opioids: overview and current issues. Drug Alcohol Depend 51:127–140.
   PubMed Web of Science ®Google Scholar
• Altieri L, Neri C, Sacco R, Curatolo P, Benvenuto A, Muratori F, Santocchi E, Bravaccio C, Lenti C, Saccani M, Rigardetto R, Gandione M, Urbani A, Persico AM. (2011). Urinary p-cresol is elevated in small children with severe autism spectrum disorder. Biomarkers 16:252–260.
   PubMed Web of Science ®Google Scholar
• Aman MG, Kern RA. (1989). Review of fenfluramine in the treatment of the developmental disabilities. j Am Acad Child Adolesc Psychiatry 28:549–565.
   PubMed Web of Science ®Google Scholar
• Amaral DG, Sinnamon HM. (1977). The locus coeruleus: neurobiology of a central noradrenergic nucleus. Prog Neurobiol 9:147–196.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. Washington DC, American Psychiatric Press.
   Google Scholar
• American Psychiatric Association (1980). Diagnostic and Statistical Manual of Mental Disorders. Washington DC, American Psychiatric Press.
   Google Scholar
• American Psychiatric Association (2010). Diagnostic and Statistical Manual of Mental Disorders.www.dsm-5.org.
   Google Scholar
• Austin DW, Shandley K. (2008). An investigation of porphyrinuria in Australian children with autism. j Toxicol Environ Health Part a 71:1349–1351.
   PubMed Web of Science ®Google Scholar
• Awad JA, Roberts LJ 2nd, Burk RF, Morrow JD. (1996). Isoprostanes–prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage. Gastroenterol Clin North Am 25:409–427.
   PubMed Web of Science ®Google Scholar
• Bacchelli E, Maestrini E. (2006). Autism spectrum disorders: molecular genetic advances. Am j Med Genet c Semin Med Genet 142C:13–23.
   Google Scholar
• Bailey WJ, Ulrich R. (2004). Molecular profiling approaches for identifying novel biomarkers. Expert Opin Drug Saf 3:137–151.
   PubMedGoogle Scholar
• Baron-Cohen S, Scott FJ, Allison C, Williams J, Bolton P, Matthews FE, Brayne C. (2009). Prevalence of autism-spectrum conditions: UK school-based population study. Br j Psychiatry 194:500–509.
   PubMed Web of Science ®Google Scholar
• Barthelemy C, Bruneau N, Cottet-Eymard JM, Domenech-Jouve J, Garreau B, Lelord G, Muh JP, Peyrin L. (1988). Urinary free and conjugated catecholamines and metabolites in autistic children. j Autism Dev Disord 18:583–591.
   PubMed Web of Science ®Google Scholar
• Barthelemy C, Bruneau N, Jouve J, Martineau J, Muh JP, Lelord G. (1989). Urinary dopamine metabolites as indicators of the responsiveness to fenfluramine treatment in children with autistic behavior. j Autism Dev Disord 19:241–254.
   PubMedGoogle Scholar
• Basu S, Dasgupta PS. (2000). Dopamine, a neurotransmitter, influences the immune system. j Neuroimmunol 102:113–124.
   PubMed Web of Science ®Google Scholar
• Bernard S, Enayati A, Roger H, Binstock T, Redwood L. (2002). The role of mercury in the pathogenesis of autism. Mol Psychiatry 7 Suppl 2:S42–S43.
   Google Scholar
• Bowers MA, Aicher LD, Davis HA, Woods JS. (1992). Quantitative determination of porphyrins in rat and human urine and evaluation of urinary porphyrin profiles during mercury and lead exposures. j Lab Clin Med 120:272–281.
   PubMed Web of Science ®Google Scholar
• Bozek P, Hutta M, Hrivnáková B. (2005). Rapid analysis of porphyrins at low ng/l and microg/l levels in human urine by a gradient liquid chromatography method using octadecylsilica monolithic columns. j Chromatogr a 1084:24–32.
   PubMedGoogle Scholar
• Bradstreet J, Geier DA, Kartzinel JJ, Adams JB, Geier MR. (2003). A case-control study of mercury burden in children with autistic spectrum disorders. J Am Phys Surg 8:4.
   Google Scholar
• Brewster MA. (1988). Biomarkers of xenobiotic exposures. Ann Clin Lab Sci 18:306–317.
   PubMed Web of Science ®Google Scholar
• Buie T, Campbell DB, Fuchs GJ 3rd, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, Winter H. (2010). Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 125 Suppl 1:S1–18.
   Google Scholar
• Bull G, Shattock P, Whiteley P, Anderson R, Groundwater PW, Lough JW, Lees G. (2003). Indolyl-3-acryloylglycine (IAG) is a putative diagnostic urinary marker for autism spectrum disorders. Med Sci Monit 9:CR422–CR425.
   PubMedGoogle Scholar
• Campbell DB, Buie TM, Winter H, Bauman M, Sutcliffe JS, Perrin JM, Levitt P. (2009). Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics 123:1018–1024.
   Google Scholar
• Careaga M, Van de Water J, Ashwood P. (2010). Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 7:283–292.
   PubMed Web of Science ®Google Scholar
• Cass H, Gringras P, March J, McKendrick I, O’Hare AE, Owen L, Pollin C. (2008). Absence of urinary opioid peptides in children with autism. Arch Dis Child 93:745–750.
   PubMed Web of Science ®Google Scholar
• Chauhan A, Chauhan V. (2006). Oxidative stress in autism. Pathophysiology 13:171–181.
   PubMedGoogle Scholar
• Chauhan A, Chauhan V, Brown WT, Cohen I. (2004). Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin–the antioxidant proteins. Life Sci 75:2539–2549.
   PubMed Web of Science ®Google Scholar
• Christian SL, Brune CW, Sudi J, Kumar RA, Liu S, Karamohamed S, Badner JA, Matsui S, Conroy J, McQuaid D, Gergel J, Hatchwell E, Gilliam TC, Gershon ES, Nowak NJ, Dobyns WB, Cook EH Jr. (2008). Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. Biol Psychiatry 63:1111–1117.
   PubMed Web of Science ®Google Scholar
• Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT. (1999). Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45:287–295.
   PubMed Web of Science ®Google Scholar
• Cohen IL, Liu X, Schutz C, White BN, Jenkins EC, Brown WT, Holden JJ. (2003). Association of autism severity with a monoamine oxidase A functional polymorphism. Clin Genet 64:190–197.
   PubMedGoogle Scholar
• Committee on Children with Disabilities (CCD). (2001). Technical report: the pediatrician’s role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics 107:E85.
   Google Scholar
• Counter SA, Buchanan LH, Ortega F, Laurell G. (2002). Elevated blood mercury and neuro-otological observations in children of the Ecuadorian gold mines. j Toxicol Environ Health Part a 65:149–163.
   PubMed Web of Science ®Google Scholar
• Croonenberghs J, Delmeire L, Verkerk R, Lin AH, Meskal A, Neels H, Van der Planken M, Scharpe S, Deboutte D, Pison G, Maes M. (2000). Peripheral markers of serotonergic and noradrenergic function in post-pubertal, caucasian males with autistic disorder. Neuropsychopharmacology 22:275–283.
   PubMed Web of Science ®Google Scholar
• D’Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, Cardi E, Giardini O. (1996). Abnormal intestinal permeability in children with autism. Acta Paediatr 85:1076–1079.
   PubMed Web of Science ®Google Scholar
• Davis BA, Durden DA, O’Reilly RL. (1991). The effect of age, sex, weight and height on the plasma concentrations in healthy subjects of the acidic metabolites of some biogenic monoamines involved in psychiatric and neurological disorders. Prog Neuropsychopharmacol Biol Psychiatry 15:503–512.
   Google Scholar
• de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, Carteni M, De Rosa M, Francavilla R, Riegler G, Militerni R, Bravaccio C. (2010). Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. j Pediatr Gastroenterol Nutr 51:418–424.
   PubMed Web of Science ®Google Scholar
• Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. (2008). How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology 29:190–201.
   PubMed Web of Science ®Google Scholar
• Dettmer K, Hanna D, Whetstone P, Hansen R, Hammock BD. (2007). Autism and urinary exogenous neuropeptides: development of an on-line SPE-HPLC-tandem mass spectrometry method to test the opioid excess theory. Anal Bioanal Chem 388:1643–1651.
   PubMed Web of Science ®Google Scholar
• Eapen V. (2011). Genetic basis of autism: is there a way forward? Curr Opin Psychiatry 24:226–236.
   PubMed Web of Science ®Google Scholar
• Editors of the Lancet. (2010). Retraction–Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 375:445.
   Google Scholar
• Eto I, Bandy MD, Butterworth CE Jr. (1992). Plasma and urinary levels of biopterin, neopterin, and related pterins and plasma levels of folate in infantile autism. j Autism Dev Disord 22:295–308.
   PubMed Web of Science ®Google Scholar
• Faustman EM, Silbernagel SM, Fenske RA, Burbacher TM, Ponce RA. (2000). Mechanisms underlying Children’s susceptibility to environmental toxicants. Environ Health Perspect 108 Suppl 1:13–21.
   Google Scholar
• Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanen PH, Granpeesheh D, Dixon D, Liu M, Molitoris DR, Green JA 3rd. (2010). Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16:444–453.
   PubMed Web of Science ®Google Scholar
• Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P, Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H, Haake DA, Manning P, Kaul A. (2002). Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 35:S6–S16.
   PubMed Web of Science ®Google Scholar
• Fitzgerald PJ. (2009). Is elevated noradrenaline an aetiological factor in a number of diseases? Auton Autacoid Pharmacol 29:143–156.
   Google Scholar
• Fuchs D, Weiss G, Wachter H. (1993). Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 101:1–6.
   PubMed Web of Science ®Google Scholar
• Garnier C, Comoy E, Barthelemy C, Leddet I, Garreau B, Muh JP, Lelord G. (1986). Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children. j Autism Dev Disord 16:23–29.
   PubMed Web of Science ®Google Scholar
• Garreau B, Barthélémy C, Jouve J, Bruneau N, Muh JP, Lelord G. (1988). Urinary homovanillic acid levels of autistic children. Dev Med Child Neurol 30:93–98.
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. (2006). A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox Res 10:57–64.
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. (2007). A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. j Toxicol Environ Health Part a 70:837–851.
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. (2007). A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. j Toxicol Environ Health Part a 70:1723–1730.
   PubMed Web of Science ®Google Scholar
• Geschwind DH, Levitt P. (2007). Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 17:103–111.
   PubMed Web of Science ®Google Scholar
• Goines P, Van de Water J. (2010). The immune system’s role in the biology of autism. Curr Opin Neurol 23:111–117.
   PubMed Web of Science ®Google Scholar
• Grahame-Smith DG. (1988). Serotonin (5-hydroxytryptamine, 5-HT). q j Med 67:459–466.
   Google Scholar
• Grandjean P, Landrigan PJ. (2006). Developmental neurotoxicity of industrial chemicals. Lancet 368:2167–2178.
   PubMed Web of Science ®Google Scholar
• Harrison KL, Pheasant AE. (1995). Analysis of urinary pterins in autism. Biochem Soc Trans 23:603S.
   Google Scholar
• Herault J, Martineau J, Perrot-Beaugerie A, Jouve J, Tournade H, Barthelemy C, Lelord G et al. (1993). Investigation of whole blood and urine monoamines in autism. Eur Child Adolesc Psychol 2: 211–220.
   Google Scholar
• Hérault J, Petit E, Martineau J, Cherpi C, Perrot A, Barthélémy C, Lelord G, Müh JP. (1996). Serotonin and autism: biochemical and molecular biology features. Psychiatry Res 65:33–43.
   Google Scholar
• Holmes AS, Blaxill MF, Haley BE. (2003). Reduced levels of mercury in first baby haircuts of autistic children. Int j Toxicol 22:277–285.
   PubMed Web of Science ®Google Scholar
• Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. (1999). Gastrointestinal abnormalities in children with autistic disorder. j Pediatr 135:559–563.
   PubMed Web of Science ®Google Scholar
• Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM, Ellison JA, Schadt EE, Verma IM, Lockhart DJ, Barlow C. (2005). Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 438:662–666.
   PubMed Web of Science ®Google Scholar
• Hranilovic D, Novak R, Babic M, Novokmet M, Bujas-Petkovic Z, Jernej B. (2008). Hyperserotonemia in autism: the potential role of 5HT-related gene variants. Coll Antropol 32 Suppl 1:75–80.
   Google Scholar
• Hunter LC, O’Hare A, Herron WJ, Fisher LA, Jones GE. (2003). Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol 45:121–128.
   PubMed Web of Science ®Google Scholar
• Israngkun PP, Newman HA, Patel ST, Duruibe VA, Abou-Issa H. (1986). Potential biochemical markers for infantile autism. Neurochem Pathol 5:51–70.
   PubMedGoogle Scholar
• James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. (2004). Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am j Clin Nutr 80:1611–1617.
   PubMed Web of Science ®Google Scholar
• Kern JK, Jones AM. (2006). Evidence of toxicity, oxidative stress, and neuronal insult in autism. j Toxicol Environ Health b Crit Rev 9:485–499.
   PubMed Web of Science ®Google Scholar
• Klauck SM, Poustka F, Benner A, Lesch KP, Poustka A. (1997). Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet 6:2233–2238.
   PubMed Web of Science ®Google Scholar
• Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van Dyck PC. (2009). Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124:1395–1403.
   PubMed Web of Science ®Google Scholar
• Lam KS, Aman MG, Arnold LE. (2006). Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 27:254–289.
   PubMed Web of Science ®Google Scholar
• Launay JM, Bursztejn C, Ferrari P, Dreux C, Braconnier A, Zarifian E, Lancrenon S, Fermanian J. (1987). Catecholamines metabolism in infantile autism: a controlled study of 22 autistic children. j Autism Dev Disord 17:333–347.
   PubMed Web of Science ®Google Scholar
• Lewis MH. (1996). Brief report: psychopharmacology of autism spectrum disorders. j Autism Dev Disord 26:231–235.
   Google Scholar
• MacDermott S, Williams K, Ridley G, Glasson E, Wray J. (2007). The prevalence of Autism in Australia can it be established from existing data? Australian Advisory Board on Autism Spectrum Disorders. Avaliable at: http://www.autismaus.com.au/index.php?page=research. Accessed on 12 April 2011.
   Google Scholar
• Main PA, Angley MT, Thomas P, O’Doherty CE, Fenech M. (2010). Folate and methionine metabolism in autism: a systematic review. Am j Clin Nutr 91:1598–1620.
   PubMed Web of Science ®Google Scholar
• Manzi B, Loizzo AL, Giana G, Curatolo P. (2008). Autism and metabolic diseases. j Child Neurol 23:307–314.
   Google Scholar
• Martineau J, Barthelemy C, Herault J, Jouve J, Muh JP. (1991). Monoamines in autistic children: A study of age-related changes. Brain Dysfunct 4:141–146.
   Google Scholar
• Martineau J, Barthélémy C, Jouve J, Muh JP, Lelord G. (1992). Monoamines (serotonin and catecholamines) and their derivatives in infantile autism: age-related changes and drug effects. Dev Med Child Neurol 34:593–603.
   PubMed Web of Science ®Google Scholar
• Martineau J, Hérault J, Petit E, Guérin P, Hameury L, Perrot A, Mallet J, Sauvage D, Lelord G, Müh JP. (1994). Catecholaminergic metabolism and autism. Dev Med Child Neurol 36:688–697.
   PubMedGoogle Scholar
• McDougle CJ, Erickson CA, Stigler KA, Posey DJ. (2005). Neurochemistry in the pathophysiology of autism. j Clin Psychiatry 66 Suppl 10:9–18.
   Google Scholar
• Messahel S, Pheasant AE, Pall H, Ahmed-Choudhury J, Sungum-Paliwal RS, Vostanis P. (1998). Urinary levels of neopterin and biopterin in autism. Neurosci Lett 241:17–20.
   Google Scholar
• Miller JS, Tallarida RJ, Unterwald EM. (2010). Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice. Brain Res Bull 82:184–187.
   Google Scholar
• Mills MJ, Savery D, Shattock PE. (1998). Rapid analysis of low levels of indolyl-3-acryloylglycine in human urine by high-performance liquid chromatography. j Chromatogr b Biomed Sci Appl 712:51–58.
   PubMedGoogle Scholar
• Minder EI, Schneider-Yin X. (1996). Age-dependent reference values of urinary porphyrins in children. Eur j Clin Chem Clin Biochem 34:439–443.
   PubMedGoogle Scholar
• Minderaa RB, Anderson GM, Volkmar FR, Akkerhuis GW, Cohen DJ. (1987). Urinary 5-hydroxyindoleacetic acid and whole blood serotonin and tryptophan in autistic and normal subjects. Biol Psychiatry 22:933–940.
   Google Scholar
• Minderaa RB, Anderson GM, Volkmar FR, Akkerhuis GW, Cohen DJ. (1989). Neurochemical study of dopamine functioning in autistic and normal subjects. j Am Acad Child Adolesc Psychiatry 28:190–194.
   PubMed Web of Science ®Google Scholar
• Minderaa RB, Anderson GM, Volkmar FR, Akkerhuis GW, Cohen DJ. (1994). Noradrenergic and adrenergic functioning in autism. Biol Psychiatry 36:237–241.
   PubMed Web of Science ®Google Scholar
• Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. (2005). Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 73:379–384.
   PubMed Web of Science ®Google Scholar
• Mitka M. (2008). Economics may play role in crowding, boarding in emergency departments. Jama 300:2714–2715.
   Google Scholar
• Molloy CA, Manning-Courtney P. (2003). Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism 7:165–171.
   PubMed Web of Science ®Google Scholar
• Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, Mukaddes NM, Balkhy S, Gascon G, Hashmi A, Al-Saad S, Ware J, Joseph RM, Greenblatt R, Gleason D, Ertelt JA, Apse KA, Bodell A, Partlow JN, Barry B, Yao H, Markianos K, Ferland RJ, Greenberg ME, Walsh CA. (2008). Identifying autism loci and genes by tracing recent shared ancestry. Science 321:218–223.
   PubMed Web of Science ®Google Scholar
• Mulder EJ, Anderson GM, Kema IP, Brugman AM, Ketelaars CE, de Bildt A, van Lang ND, den Boer JA, Minderaa RB. (2005). Serotonin transporter intron 2 polymorphism associated with rigid-compulsive behaviors in Dutch individuals with pervasive developmental disorder. Am j Med Genet b Neuropsychiatr Genet 133B:93–96.
   PubMed Web of Science ®Google Scholar
• Mulder EJ, Anderson GM, Kemperman RF, Oosterloo-Duinkerken A, Minderaa RB, Kema IP. (2010). Urinary excretion of 5-hydroxyindoleacetic acid, serotonin and 6-sulphatoxymelatonin in normoserotonemic and hyperserotonemic autistic individuals. Neuropsychobiology 61:27–32.
   Google Scholar
• Mulder EJ, Oosterloo-Duinkerken A, Anderson GM, De Vries EG, Minderaa RB, Kema IP. (2005). Automated on-line solid-phase extraction coupled with HPLC for measurement of 5-hydroxyindole-3-acetic acid in urine. Clin Chem 51:1698–1703.
   Google Scholar
• Mutter J, Naumann J, Schneider R, Walach H, Haley B. (2005). Mercury and autism: accelerating evidence? Neuro Endocrinol Lett 26:439–446.
   PubMed Web of Science ®Google Scholar
• Nataf R, Skorupka C, Amet L, Lam A, Springbett A, Lathe R. (2006). Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol 214:99–108.
   PubMed Web of Science ®Google Scholar
• Nataf R, Skorupka C, Lam A, Springbett A, Lathe R. (2008). Porphyrinuria in childhood autistic disorder is not associated with urinary creatinine deficiency. Pediatr Int 50:528–532.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Connelly J, Lindon JC, Holmes E. (2002). Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1:153–161.
   PubMed Web of Science ®Google Scholar
• Nieoullon A. (2002). Dopamine and the regulation of cognition and attention. Prog Neurobiol 67:53–83.
   PubMed Web of Science ®Google Scholar
• Niimi K, Takahashi E, Itakura C. (2009). Analysis of motor function and dopamine systems of SAMP6 mouse. Physiol Behav 96:464–469.
   Google Scholar
• Oliveira G, Diogo L, Grazina M, Garcia P, Ataíde A, Marques C, Miguel T, Borges L, Vicente AM, Oliveira CR. (2005). Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 47:185–189.
   PubMed Web of Science ®Google Scholar
• Palmer RF, Blanchard S, Stein Z, Mandell D, Miller C. (2006). Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place 12:203–209.
   PubMed Web of Science ®Google Scholar
• Pardo CA, Eberhart CG. (2007). The neurobiology of autism. Brain Pathol 17:434–447.
   PubMed Web of Science ®Google Scholar
• Parracho HM, Bingham MO, Gibson GR, McCartney AL. (2005). Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 54:987–991.
   PubMed Web of Science ®Google Scholar
• Pedersen OS, Liu Y, Reichelt KL. (1999). Serotonin uptake stimulating peptide found in plasma of normal individuals and in some autistic urines. j Pept Res 53:641–646.
   PubMedGoogle Scholar
• Redwood L, Bernard S, Brown D. (2001). Predicted mercury concentrations in hair from infant immunizations: cause for concern. Neurotoxicology 22:691–697.
   PubMed Web of Science ®Google Scholar
• Reichelt WH, Knivsberg AM, Nadland M, Stensrud M, Reichelt KL. (1997). Urinary peptide levels and patterns in autistic children from seven countries, and the effect of dietary intervention after 4 years. Dev Brain Dysfunct 10:44–55.
   Google Scholar
• Roy A, Pickar D, De Jong J, Karoum F, Linnoila M. (1988). Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry 45:849–857.
   PubMedGoogle Scholar
• Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, Nelson MN, Wexler HM. (2000). Short-term benefit from oral vancomycin treatment of regressive-onset autism. j Child Neurol 15:429–435.
   PubMed Web of Science ®Google Scholar
• Schultz W. (1998). Predictive reward signal of dopamine neurons. j Neurophysiol 80:1–27.
   PubMed Web of Science ®Google Scholar
• Shattock P, Kennedy A, Rowell F, Berney T. (1990). Role of neuropeptides in autism and their relationships with classical neurotransmitters. Brain Dysfunct 3:328–345.
   Google Scholar
• Shattock P, Whiteley P. (2002). Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets 6:175–183.
   PubMedGoogle Scholar
• Shaw W. (2010). Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia. Nutr Neurosci 13:135–143.
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634–e641.
   PubMed Web of Science ®Google Scholar
• Sher L. (1997). Autistic disorder and the endogenous opioid system. Med Hypotheses 48:413–414.
   Google Scholar
• Slotkin TA, Levin ED, Seidler FJ. (2006). Comparative developmental neurotoxicity of organophosphate insecticides: effects on brain development are separable from systemic toxicity. Environ Health Perspect 114:746–751.
   PubMed Web of Science ®Google Scholar
• Soden SE, Lowry JA, Garrison CB, Wasserman GS. (2007). 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila) 45:476–481.
   Web of Science ®Google Scholar
• Song Y, Liu C, Finegold SM. (2004). Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol 70:6459–6465.
   PubMed Web of Science ®Google Scholar
• Stangle DE, Smith DR, Beaudin SA, Strawderman MS, Levitsky DA, Strupp BJ. (2007). Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. Environ Health Perspect 115:201–209.
   PubMed Web of Science ®Google Scholar
• Stigler KA, Sweeten TL, Posey DJ, McDougle CJ. (2009). Autism and immune factors: A comprehensive review. Res Autism Spect Dis 3:840–860.
   Web of Science ®Google Scholar
• Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu XQ, Vincent JB, et al. (2007). Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 39:319–328.
   PubMed Web of Science ®Google Scholar
• Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA. (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351:637–641.
   PubMed Web of Science ®Google Scholar
• Wang L, Angley MT, Gerber JP, Young RL, Abarno DV, McKinnon RA, Sorich MJ. (2009). Is urinary indolyl-3-acryloylglycine a biomarker for autism with gastrointestinal symptoms? Biomarkers 14:596–603.
   PubMed Web of Science ®Google Scholar
• Wang L, Angley MT, Sorich MJ, Young RL, McKinnon RA, Gerber JP. (2010). Is there a role for routinely screening children with autism spectrum disorder for creatine deficiency syndrome? Autism Res 3:268–272.
   Google Scholar
• Weber W, Newmark S. (2007). Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 54:983–1006; xii.
   Google Scholar
• Whitaker-Azmitia PM. (2001). Serotonin and brain development: role in human developmental diseases. Brain Res Bull 56:479–485.
   PubMed Web of Science ®Google Scholar
• Whiteley P, Rodgers J, Savery D, Shattock P. (1999). A gluten-free diet as an intervention for autism and associated spectrum disorders: Preliminary findings. Autism 3:45–65.
   Google Scholar
• Whiteley P, Shattock P. (2003). What makes trans-indolyl-3-acryloylglycine identified by high-performance liquid chromatography relevant to pervasive developmental disorders? J Nutr Environ Med 13:231–237.
   Google Scholar
• Whiteley P, Waring R, Williams L, Klovrza L, Nolan F, Smith S, Farrow M, Dodou K, Lough WJ, Shattock P. (2006). Spot urinary creatinine excretion in pervasive developmental disorders. Pediatr Int 48:292–297.
   PubMed Web of Science ®Google Scholar
• Wing L.(1996). The Autistic Spectrum - A Guide for Parents and Professionals. London: Constable & Robinson Ltd.
   Google Scholar
• Woods JS, Echeverria D, Heyer NJ, Simmonds PL, Wilkerson J, Farin FM. (2005). The association between genetic polymorphisms of coproporphyrinogen oxidase and an atypical porphyrinogenic response to mercury exposure in humans. Toxicol Appl Pharmacol 206:113–120.
   PubMed Web of Science ®Google Scholar
• Woods JS, Kardish RM. (1983). Developmental aspects of hepatic heme biosynthetic capability and hematotoxicity-II. Studies on uroporphyrinogen decarboxylase. Biochem Pharmacol 32:73–78.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). (1992). The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization. Geneva.
   Google Scholar
• Wright B, Brzozowski AM, Calvert E, Farnworth H, Goodall DM, Holbrook I, Imrie G, Jordan J, Kelly A, Miles J, Smith R, Town J. (2005). Is the presence of urinary indolyl-3-acryloylglycine associated with autism spectrum disorder? Dev Med Child Neurol 47:190–192.
   PubMed Web of Science ®Google Scholar
• Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. (2010). Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. j Proteome Res 9:2996–3004.
   PubMed Web of Science ®Google Scholar
• Yorbik O, Kurt I, Hasimi A, Oztürk O. (2010). Chromium, cadmium, and lead levels in urine of children with autism and typically developing controls. Biol Trace Elem Res 135:10–15.
   Web of Science ®Google Scholar
• Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. (2002). Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 67:341–343.
   PubMed Web of Science ®Google Scholar
• Young JG, Kavanagh ME, Anderson GM, Shaywitz BA, Cohen DJ. (1982). Clinical neurochemistry of autism and associated disorders. j Autism Dev Disord 12:147–165.
   PubMed Web of Science ®Google Scholar
• Zafeiriou DI, Ververi A, Vargiami E. (2009). The serotonergic system: its role in pathogenesis and early developmental treatment of autism. Curr Neuropharmacol 7:150–157.
   PubMed Web of Science ®Google Scholar
• Zecavati N, Spence SJ. (2009). Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep 9:129–136.
   Google Scholar